TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

TG Therapeutics Inc.

TG Therapeutics ( ($TGTX) ) has provided an update. At its 2026 Annual Meeting held online on June 11, 2026, TG Therapeutics reported that stockhol...

TG Therapeutics Shareholders Reject Executive Compensation at Meeting

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TG Therapeutics (TGTX) and AbbVie (ABBV) with bullis...

Analysts’ Top Healthcare Picks: TG Therapeutics (TGTX), AbbVie (ABBV)

An announcement from TG Therapeutics ( ($TGTX) ) is now available. On May 27, 2026, TG Therapeutics announced positive topline results from its Pha...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TGTX	$53.94	-0.85%	3.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TGTX	$53.94	-0.8%	3.12M
3
4
5
6

TGTX

TGTX

Recent News for TGTX

Get TG Therapeutics Inc. Data in Excel

Get TG Therapeutics Inc. Data in Excel